631 filings
Page 23 of 32
8-K
NBSE
NeuBase Therapeutics Inc
20 Oct 14
Reduction of Subretinal Hyperreflective Material (SHRM) Induced by OHR-102 Correlates with Improved Vision Outcomes
12:00am
8-K
NBSE
NeuBase Therapeutics Inc
14 Oct 14
Ohr Pharmaceutical Announces Successful End of Phase II Meeting with the FDA on Squalamine Eye Drops (OHR-102) in Wet AMD
12:00am
10-Q
2014 Q3
NBSE
NeuBase Therapeutics Inc
Quarterly report
18 Aug 14
12:00am
NT 10-Q
NBSE
NeuBase Therapeutics Inc
14 Aug 14
Notice of late quarterly filing
12:00am
8-K
NBSE
NeuBase Therapeutics Inc
13 Aug 14
Ohr Pharmaceutical Announces Additional Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Wet-AMD; The IMPACT Study
12:00am
8-K/A
NBSE
NeuBase Therapeutics Inc
13 Aug 14
Report of Independent Registered Public Accounting Firm
12:00am
8-K
NBSE
NeuBase Therapeutics Inc
11 Aug 14
Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Retinal Vein Occlusion
12:00am
SC 13G
Visium Asset Management, LP
11 Jul 14
Ohr Pharmaceutical Inc
12:00am
8-K
NBSE
NeuBase Therapeutics Inc
24 Jun 14
Regulation FD Disclosure
12:00am
D
NBSE
NeuBase Therapeutics Inc
4 Jun 14
$25.18M in equity, sold $10.18M, 1 investor
12:00am
8-K
NBSE
NeuBase Therapeutics Inc
2 Jun 14
Strengthens Executive Management Team
12:00am
8-K
NBSE
NeuBase Therapeutics Inc
16 May 14
Ohr Pharmaceutical Announces Agreement to Acquire Technology Assets of SKS Ocular
12:00am
10-Q
2014 Q2
NBSE
NeuBase Therapeutics Inc
Quarterly report
13 May 14
12:00am
8-K
NBSE
NeuBase Therapeutics Inc
9 May 14
Ohr Pharmaceutical Announces Initiation of Investigator Sponsored Trial of Squalamine Eye Drops in Diabetic Macular Edema
12:00am
8-K
NBSE
NeuBase Therapeutics Inc
29 Apr 14
Ohr Pharmaceutical Announces Completion of Enrollment in Phase II Clinical Trial of Squalamine Eye Drops in Wet-AMD
12:00am
8-K
NBSE
NeuBase Therapeutics Inc
14 Apr 14
Departure of Directors or Certain Officers
12:00am
S-3MEF
NBSE
NeuBase Therapeutics Inc
8 Apr 14
Registration of additional securities for an S-3
12:00am
424B5
NBSE
NeuBase Therapeutics Inc
8 Apr 14
Prospectus supplement for primary offering
12:00am
8-K
NBSE
NeuBase Therapeutics Inc
8 Apr 14
Ohr Pharmaceutical Announces $18 Million Registered Direct Offering of Common Stock
12:00am